BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15245816)

  • 1. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study.
    Pectasides D; Pectasides M; Farmakis D; Aravantinos G; Nikolaou M; Koumpou M; Gaglia A; Kostopoulou V; Mylonakis N; Economopoulos T; Raptis SA
    Eur Urol; 2004 Aug; 46(2):216-21. PubMed ID: 15245816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study.
    Pectasides D; Pectasides M; Farmakis D; Aravantinos G; Nikolaou M; Koumpou M; Gaglia A; Kostopoulou V; Mylonakis N; Skarlos D
    Ann Oncol; 2004 Mar; 15(3):493-7. PubMed ID: 14998855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
    Kollmannsberger C; Rick O; Derigs HG; Schleucher N; Schöffski P; Beyer J; Schoch R; Sayer HG; Gerl A; Kuczyk M; Spott C; Kanz L; Bokemeyer C
    J Clin Oncol; 2002 Apr; 20(8):2031-7. PubMed ID: 11956262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer.
    Motzer RJ; Sheinfeld J; Mazumdar M; Bains M; Mariani T; Bacik J; Bajorin D; Bosl GJ
    J Clin Oncol; 2000 Jun; 18(12):2413-8. PubMed ID: 10856101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.
    Soulié P; Garrino C; Bensmaïne MA; Bekradda M; Brain E; Di Palma M; Goupil A; Misset JL; Cvitkovic E
    J Cancer Res Clin Oncol; 1999 Dec; 125(12):707-11. PubMed ID: 10592105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors.
    Miki T; Mizutani Y; Nonomura N; Nomoto T; Nakao M; Saiki S; Kotake T; Okuyama A
    Cancer; 2002 Nov; 95(9):1879-85. PubMed ID: 12404281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
    Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
    Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
    Scheithauer W; Kornek GV; Raderer M; Valencak J; Weinländer G; Hejna M; Haider K; Kwasny W; Depisch D
    J Clin Oncol; 1999 Mar; 17(3):902-6. PubMed ID: 10071282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support for the treatment of refractory or relapsed small-cell lung cancer.
    Fujita A; Takabatake H; Tagaki S; Sekine K
    Oncology; 2000 Aug; 59(2):105-9. PubMed ID: 10971167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
    Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.
    Kollmannsberger C; Rick O; Klaproth H; Kubin T; Sayer HG; Hentrich M; Welslau M; Mayer F; Kuczyk M; Spott C; Kanz L; Bokemeyer C
    Br J Cancer; 2002 Sep; 87(7):729-32. PubMed ID: 12232755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage chemotherapy with gemcitabine plus oxaliplatin for patients with testicular germ cell cancer.
    Uchida M; Kawai K; Kimura T; Ichioka D; Takaoka E; Suetomi T; Miyazaki J; Nishiyama H
    Int J Clin Oncol; 2014 Dec; 19(6):1112-7. PubMed ID: 24647526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach.
    Badreldin W; Krell J; Chowdhury S; Harland SJ; Mazhar D; Harding V; Frampton AE; Wilson P; Berney D; Stebbing J; Shamash J
    BJU Int; 2016 Mar; 117(3):418-23. PubMed ID: 25430674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience.
    De Giorgi U; Rosti G; Papiani G; Aieta M; Fochessati F; Paoluzzi L; Valduga F; Marangolo M
    Am J Clin Oncol; 2004 Oct; 27(5):457-60. PubMed ID: 15596910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
    Kollmannsberger C; Beyer J; Liersch R; Schoeffski P; Metzner B; Hartmann JT; Rick O; Stengele K; Hohloch K; Spott C; Kanz L; Bokemeyer C
    J Clin Oncol; 2004 Jan; 22(1):108-14. PubMed ID: 14701772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours.
    Shamash J; Powles T; Mutsvangwa K; Wilson P; Ansell W; Walsh E; Berney D; Stebbing J; Oliver T
    Ann Oncol; 2007 May; 18(5):925-30. PubMed ID: 17355956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.
    de Jonge MJ; Sparreboom A; Planting AS; van der Burg ME; de Boer-Dennert MM; ter Steeg J; Jacques C; Verweij J
    J Clin Oncol; 2000 Jan; 18(1):187-94. PubMed ID: 10623709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.
    Kondagunta GV; Bacik J; Donadio A; Bajorin D; Marion S; Sheinfeld J; Bosl GJ; Motzer RJ
    J Clin Oncol; 2005 Sep; 23(27):6549-55. PubMed ID: 16170162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
    Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
    Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
    Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C
    Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.